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Abstract: Longitudinal bone growth occurs through endochondral ossification (EO), controlled by
various signaling molecules. Retinoid X Receptor (RXR) is a nuclear receptor with important roles in
cell death, development, and metabolism. However, little is known about its role in EO. In this study,
the agonist SR11237 was used to evaluate RXR activation in EO. Rats given SR11237 from post-natal
day 5 to post-natal day 15 were harvested for micro-computed tomography (microCT) scanning and
histology. In parallel, newborn CD1 mouse tibiae were cultured with increasing concentrations of
SR11237 for histological and whole-mount evaluation. RXR agonist-treated rats had shorter long
bones than the controls and developed dysmorphia of the growth plate. Cells invading the calcified
and dysmorphic growth plate appeared pre-hypertrophic in size and shape, in correspondence with
p57 immunostaining. Additionally, SOX9-positive cells were found surrounding the calcified tissue.
The epiphysis of SR11237-treated bones showed increased TRAP staining and additional TUNEL
staining at the osteo-chondral junction. MicroCT revealed morphological disorganization in the long
bones of the treated animals. This study suggests that stimulation of RXR causes irregular ossification,
premature closure of the growth plate, and disrupted long bone growth in rodent models
Keywords: osteoarthritis; retinoid X receptor; endochondral ossification; chondrocytes
1. Introduction
Longitudinal bone growth occurs through the process of endochondral ossification, in which
a cartilaginous model first expands through the activity of chondrocytes and then is replaced by
bone. Endochondral ossification begins with the condensation of mesenchymal cells that subsequently
differentiate into chondrocytes, the primary cell type of cartilage. Chondrocytes begin expressing
SRY (sex-determining region Y)-box9 (SOX9) and synthesize a matrix comprised largely of type II
collagen and the proteoglycan aggrecan [1]. These early cartilage cells have a distinct rounded shape,
are scattered irregularly throughout the matrix, divide infrequently, and give rise to resting chondrocytes.
Eventually, the resting cells begin to divide more rapidly and enter the proliferative zone, although the
driving force behind this shift in activity is not completely known [2]. While in the proliferating zone,
cells appear flattened. Upon division, their daughter cells line up in columns along the longitudinal axis
of the bone. The elongated shape and the longitudinal growth of endochondral bones are largely due
to this spatial orientation [2], with chondrocyte proliferation as one key factor influencing longitudinal
Int. J. Mol. Sci. 2019, 20, 5198; doi:10.3390/ijms20205198 www.mdpi.com/journal/ijms
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bone growth. Chondrocytes in the center of the cartilage eventually cease to proliferate and exit
the cell cycle to become hypertrophic cells. Chondrocytes undergoing hypertrophy increase up to
20-fold in size [3], stop synthesizing SOX9, and begin expressing type X collagen instead of type II.
Hypertrophic differentiation is driven by transcription factors such as runt-related transcription factor
2 (RUNX2) [4–6] and myocyte enhancer factor-2c (MEF2C) [7] that is required for Runx2 expression [1].
Hypertrophic chondrocytes release signals to attract blood vessels, osteoclasts invade the matrix
to resorb the cartilage, and trabecular bone formation initiates. During this process, hypertrophic
chondrocytes either undergo apoptosis or trans-differentiate into osteoblasts [1,8,9]. Processes occur in
the center of the cartilage template, forming the primary ossification center. A secondary ossification
center forms later at the end of the template through a similar process. The growth plate consists
of the chondrocytes located between these two areas of ossification, with distinctly divided zones
of resting, proliferating, and hypertrophic cells [10]. Throughout this process, proliferation and
hypertrophy of chondrocytes drive the longitudinal growth of the bone [11]. A complex array of
hormones and signaling molecules control the process of endochondral ossification [12]. Dysregulation
of any of the factors controlling growth plate function can cause defects including reduced bone
length, altered mineralization, and skeletal deformities, such as seen in chondrodysplasias [1,5,10–12].
Understanding these processes is crucial to elucidating the etiology of bone diseases along with
developing interventions to ameliorate any adverse outcomes.
Retinoid X Receptor (RXR) is a type 2 nuclear receptor that is part of the steroid/thyroid hormone
superfamily. It has important roles in cell death, development, metabolism, and cell differentiation [13]
and is expressed in almost every tissue of the body [14]. There are three different RXR proteins (alpha,
beta, and gamma), and each is expressed in a cell type-dependent manner [13]. RXR has the ability to
form homodimers or heterodimers with other nuclear receptors in a permissive or non-permissive
way [15,16]. Permissive heterodimers can be activated by agonists for either partner in the dimer and
include RXR dimers with peroxisome proliferator-activated receptors (PPARs), farnesoid X receptors
(FXRs), and liver X receptors (LXRs). Non-permissive dimers can only be activated by the ligand for the
partner (not by RXR ligands) and include retinoic acid receptors (RARs), vitamin D receptors (VDRs),
and thyroid hormone receptors (TRs). Given that RXR homodimerizes with itself and heterodimerizes
with several nuclear receptors, thereby regulating the downstream transcription of multiple genes,
the direct influence of RXR alone on development has been difficult to elucidate. The RXR binding
partner most broadly studied in relation to rodent development is RAR. Although this complex is
important for many processes in development, the most profound effects of RXR–RAR heterodimers
have been discovered in embryonic bone. For example, exposure to retinoic acid during embryonic
development causes skeletal element deletions and truncations in the forelimbs [17]. While RXR is
involved in these processes, the RXR–RAR heterodimer is primarily activated by an RAR agonist [18].
It remains to be studied how RXR homodimers would affect bone development without the influence
of any other binding partner. Although the impact of RXR itself is far-reaching, little is known about
its relevance in long bone development. To determine its importance, the RXR-specific pan-agonist
SR11237 [19] was used in this study to identify the effects of RXR activation on rat endochondral
bone development.
2. Results
2.1. RXR Activation Results in Reduced Body Weight and Bone Length
Newborn rats were injected with DMSO or SR11237 daily from P5 to P15. Daily treatment with
vehicle or SR11237 had no effects on maternal behavior or neonatal mortality. At P16, the animals were
weighed before sacrifice. The RXR agonist-treated animals of both sexes weighed 30% less than the
DMSO-injected controls (Figure 1A,B). Humerus, tibia, femur, and radius were dissected from the
right side of all Sprague-Dawley pups and measured for length. A non-parametric Mann–Whitney
unpaired two-tailed t-test showed that the femur, tibia, and radius bones were significantly shorter
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in the females injected with SR11237 than in the DMSO controls (Figure 1C,D). All four bones were
significantly shorter in the males injected with SR11237 than in the DMSO controls (Figure 1C,D).
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Tibiae were isolated from newborn mice and cultured for 4 days with DMSO (control) or 
differing concentrations of the RXR agonist SR11237. The total length of bones was measured at the 
beginning and end of the culture period to determine the longitudinal growth (Figure 2). Treatment 
of tibiae with 5 μM SR11237 (Figure 2A) caused a decrease in length in comparison to all other 
conditions, but statistical significance was only observed in comparison to the 1 μM treatment. 
Safranin O/Fast Green staining of tibia sections confirmed that DMSO-treated tibiae were longer than 
tibiae treated with 5 μM SR11237 (Figure 2B). 
Figure 1. Retinoid X Receptor (RXR) agonist treatment results in reduced weight and bone length in
rats. At P16, male (A) and female (B) animals were weighed before sacrifice (N = 5; mean ± SEM;
Mann–Whitney unpaired two tailed t-test; p < 0.005). Bone lengths were measured at P16 in male (C)
and female (D) rats following sacrifice. All RXR agonist-treated bones in the males were found to be
significantly shorter than control bones, and in the females, the femur, tibia, and radius treated with the
RXR agonist were significantly shorter than the control bones (N = 5; mean ± SEM; Mann–Whitney
unpaired two-tailed t-test; * p < 0.005).
2.2. The RXR Agonist SR11237 Decreases Total Length Change in Cultured Mouse Tibiae
Tibiae were isolated from newborn mice and cultured for 4 days with DMSO (control) or differing
concentrations of the RXR agonist SR11237. The total length of bones was measured at the beginning
and end of the culture period to determine the longitudinal growth (Figure 2). Treatment of tibiae
with 5 µM SR11237 (Figure 2A) caused a decrease in length in comparison to all other conditions,
but statistical significance was only observed in comparison to the 1 µM treatment. Safranin O/Fast
Green staining of tibia sections confirmed that DMSO-treated tibiae were longer than tibiae treated
with 5 µM SR11237 (Figure 2B).
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treatment (A) (N = 5; mean ± SEM; Kruskal–Wallis one-way ANOVA with Dunn’s post-hoc test; * p < 
0.005). The DMSO -treated tibia (top) is trending to be longer than the tibia treated with 5 μM SR11237 
(bottom) (B). 
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The left limbs of P16 male rats treated with RXR agonist or control were harvested for Micro-
computed tomography (microCT) analysis. The shape and size of all long bones changed 
substantially upon treatment with the RXR agonist. The images demonstrated a significant size 
reduction in the fore- and hindlimbs treated with SR11237 compared to the DMSO control-treated 
limbs (Figure 3A,B). Regions of increased and decreased radio-opacity could be seen in all bones of 
the fore- and hindlimbs, scapula, hands, and feet upon RXR agonist treatment (Figure 3A–E). These 
scans indicated that the scapula showed less calcification in the center of the bone, but thicker 
calcification along the outer rim in the animals treated with the RXR agonist (Figure 3C). Metacarpals 
and metatarsals of the hands and feet appeared dysmorphic, under-calcified, and under-developed 
Figure 2. The RXR agonist SR 11237 decreases bone growth in murine tibiae in vitro. P0 tibiae were
isolated and cultured for 4 days with DMSO and various concentrations of SR11237. The total length of
bones was measured following isolation and upon experimental completion to determine the percentage
of longitudinal growth. Treatment of tibia with 5 µM SR11237 caused a decrease in growth compare to
all other conditions, but significance was only observed in comparison to the 1 µM treatment (A) (N = 5;
mean ± SEM; Kruskal–Wallis one-way ANOVA with Dunn’s post-hoc test; * p < 0.005). The DMSO
-treated tibia (top) is trending to be longer than the tibia treated with 5 µM SR11237 (bottom) (B).
2.3. MicroCT Analyses Shos Abnormal Bone Morphology in RXR Agonist-Treated Rats
The left limbs of P16 male rats treated with RXR agonist or control were harvested for
Micro-computed tomography (microCT) analysis. The shape and size of all long bones changed
substantially upon treatment with h RXR agonist. The images demonstrated a ignificant size
reduction in the fore- and h ndlimbs treated wit SR11237 compar d to the DMSO control-treat
limbs (F gure 3A,B). Regio s of increased and decreased radio-opacity could be seen in all bones
of the fore- and hindlimbs, scapula, hands, and feet upon RXR agonis treatment (Figure 3A–E).
These scans indicated that the scapul showed l ss calcific tion in the center of th bone, but thicker
calcification alo g the outer rim in the animals treated with the RXR agonist (Figure 3C). Metacarpals
and metatarsals of the hands and feet appeared dysmorphic, und r-calcified, and under-develop d
in treated rats (Figur 3D,E). SR11237 treatment resulted in the disruption of the development of the
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secondary ossification centers, as well as in the reduction of the size of mineralization of the smaller
bones of the hands and feet (Figure 3D,E).
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Figure 3. microCT (µCT) Images of P16 RXR and control male rats show abnormal morphology.
ore- and h ndlimbs bones of control rats were longe and thicker than those of RXR agonist-treated
imals (A,B). The scapulae of RXR agonist-treated animals had increased radio-opacity i the c nter
of the bone, but more calcification l g he outer edges when compared to those of the animals
treated with DMSO (C). The me acarpals and metatarsals of the hands and feet appeared dysmorphic,
under-calcified, and under-developed in the animals trea ed with the RXR agonist (D,E) (N = 5;
50 micrometers/voxel).
2.4. Disrupted Growth Plate Morphology in P16 Male Rat Long Bones
Paraffin sections of humerus, tibia, and femur fr m the P16 rats were stained with Safranin
O/fast green (Figure 4). This staining highlighted greatly disturbed growth plate organization and
the apparent fusion of the primary and secondary ossification centers in the RXR agonist-treated
animals versus DMSO controls. RXR activation by SR11237 caused premature growth plate closure and
an infiltration of ossified tissue through the central epiphysis of the bones, effectively joining together
the primary and secondary ossification centers. Importantly, the tibia appeared to be more afflicted
Int. J. Mol. Sci. 2019, 20, 5198 6 of 14
than the humerus and the femur (Figure 4). Females showed a similar but less severe phenotype than
males (Figure S1).
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Figure 4. Disrupted growth plate morphology in P16 male rat long bones. Safranin O/fast green
staining of bone sections highlights the ap earance of disturbed growth plate organiz tio and fusion
of primary and s condary ossification c nters in RXR agonist-treated males. Higher m gnification in
inset (scale bar = 1000 µm; inset = 500 µm).
2.5. Immunohistochemistry and Histological Staining of P16 Rat Tibial Sections
We performed histological and immunohistological analyses to further characterize the observed
phenotypes. SOX9 (a marker for early and proliferating chondrocytes) expression was found
in growth-plate chondrocytes in control rats and in the cells surrounding the calcified tissue in
SR11237-treated rats (Figure 5). The cartilage of SR11237-treated animals showed reduced numbers
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of chondrocytes staining positive for PCNA, a marker of cell proliferation, and P57, a marker of
post-mitotic and pre-hypertrophic chondrocytes (Figure 5). In contrast, the central epiphysis of
SR11237-treated rats was highly positive for TRAP and picro-sirius red staining, suggesting increased
osteoclast activity and accelerated replacement of cartilage by bone (Figure 6). TUNEL staining showed
concentrated cell death at the osteo–chondral junction of the growth plate in both groups (Figure 6).
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Figure 5. Immunohistochemistry staining of P16 rat tibial sections. Sections of tibiae from rats treated
with DMSO or SR11237 were examined by immunohistochemistry for various markers. PCNA is
a proliferative marker; P57 demonstrates the arrangement of terminally differentiating chondrocytes in
the hypertrophic region; SOX9 shows the organization of proliferating chondrocytes (scale bar = 200µm).
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(with the exception of the female humerus, which was not significantly shorter). At present it is 
unclear whether the effects on body weight are due to systemic and metabolic effects or secondary to 
reduced bone growth. However, the reduced growth of tibiae cultured with the high concentration 
Figure 6. Histological staining of P16 rat tibial sections. Sections of tibiae from rats treated with DMSO
or SR11237 were examined by staining for various markers. TUNEL detects cell death; active osteoclasts
are stained by TRAP; picro-sirius red stains collagen fibers (scale bar = 200 µm).
3. Discussion
This study examines the effects of RXR agonist administration on rodent endochondral ossification
and growth plate biology. By activating RX specifically in the ea ly newborn stage, pri r t and
during the onset of second ry ossification, using the RXR agonist SR11237, we found adverse ffects
on the growth plate of rat long bones, as well s effects on body size, bone formation, and morphology
of multiple skeletal elements. Previ us studies had ex mined the effects of other RXR agonists on
bone arameters b t were largely focus d on adult stages [20]. Similarly, mice with specific deletions
of the RXRα and RXRβ gen s in hematopoietic cells showed defect in o teoclast function but were
studied at later stages only [21]. The RXR agonist-tr ated animals of both sexes w re significantly
smaller (30%) than their littermate DMSO-i jected siblings. This size difference w s present until
sacrifice at P16. Simil rly, all four lo g bones dissected (tibia, femur, humerus, and radius) were
significantly shorter in the animals injected with SR11237 compar d to DMSO controls (with the
exception of the female humerus, whic w s not ig ificantly s orter). At present it is unclear whether
the effects on body weight ar du to systemic and metabolic effects or secondary to reduced bone
growth. However, the reduced gro th of tibiae cultured with the high conc ntrati n of the RXR
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agonist suggests that at least a portion of the growth retardation observed was due to direct effects on
growth-plate chondrocytes. The effects of the RXR pan-agonist SR11237 on endochondral ossification
was further evaluated in a mouse ex vivo model to further focus on direct effects on the skeleton and
validate our findings in a second species. The growth of the mouse long bones was reduced by the
treatment with 5 µM SR11237 (at least in comparison to the 1 µM treatment), further emphasizing the
profound effects of RXR stimulation during long bone development and growth. The mouse ex vivo
experiments were done for a shorter duration (4 days) than the in vivo studies (10 days), providing
one potential reason for the somewhat lower effects of SR11237 in this model. Additional possible
explanations include age of the animals (P0 versus P10), species differences, and indirect effects of
SR11237 through other organs (such as endocrine glands) in the rat model.
MicroCT imaging of the rats demonstrated that the fore- and hindlimbs of the SR11237-injected
animals were thinner and appeared somewhat osteopenic. Skeletal staining with Alcian Blue and
Alizarin Red revealed similar findings. The metacarpals and metatarsals of the hands and feet appeared
dysmorphic, undercalcified, and underdeveloped. Although both sexes appeared to be afflicted,
males appeared more impaired than females. Safranin O/ fast green staining of long bone sections
highlighted disturbed growth plate organization and the disruption of the primary and secondary
ossification centers in the RXR agonist-treated animals versus the DMSO controls. Cells surrounding
the disrupted growth plate and ossification centers were largely pre-hypertrophic in size and shape.
Again, males appeared to be more affected than females. Importantly, the tibia appeared to be more
afflicted than the humerus and the femur. In all staining and immunohistochemical experiments,
sections from both male and female rats were used. However, in every instance, males appeared to
be more afflicted than females. P57, SOX9, and PCNA immunohistochemistry was performed on
tibia, humerus, and femur sections. All three markers were present in control animals in the expected
patterns, but the staining patterns in the animals treated with SR11237 further demonstrated the
extreme disorganization of the growth plate. Upon RXR activation, PCNA, P57, and SOX9 were found
in the cells surrounding the central ossified section in no particular spatial order, suggesting that the
overall organized structure of the zones of the growth plate was lost, and chondrocytes of various
maturation stages were intermingled. The reduced number of PCNA-positive chondrocytes upon
SR11237 administration suggests that RXR activation drives the cells out of the cell cycle, which could
contribute to reduced bone growth and to the closure of the growth plate. Although it was difficult
to tell if the SR11237-injected animals were more afflicted than their DMSO controls, the pattern of
TUNEL staining appeared to be moderately different. Generally, the highest amount of cell death in
a typically developing growth plate occurs in the late hypertrophic zone, where some chondrocytes
are undergoing apoptosis and osteoclasts are invading [22]. However, in the SR11237-treated animals,
TUNEL-positive cells appeared most consistently around the infiltration of ossified tissue through the
growth plate, seemingly in no particular order, again demonstrating the intermingling of multiple
chondrocyte types in the same space. However, there did appear to be an increase in cell death at
the osteo–chondral junction, which is consistent with the normal transition, as some hypertrophic
cells undergo apoptosis. The highly localized pattern of TUNEL staining also suggests that the severe
phenotypes observed are not due to general cellular toxicity induced by the RXR agonist.
In the DMSO control animal growth plate, TRAP staining occurs only at the site where the
hypertrophic cartilage transitions to bone and around the area of secondary ossification. In the RXR
agonist-treated animals, TRAP staining was found throughout the central epiphysis of the bone and
connected the primary and secondary ossification centers completely. The staining appeared very
intense and prevalent throughout, suggesting that osteoclast activation or recruitment is one of the
main responses to RXR activation.
Picro-sirius red stains collagen fibers and is particularly strong in bone tissue. Control animals
showed picro-sirius staining concentrated at the primary and secondary ossification centers, but only
weak staining in the area of the growth plate. Upon RXR activation, the area and intensity of
staining appeared greatly increased, further supporting our finding of increased bone formation and
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highlighting the fusion of primary and secondary ossification centers. Future work will need to address
whether the effects outlined in this study are due to RXR action itself or involve any of its heterodimeric
partners. Potential candidates include the vitamin D receptor (VDR), since it stimulates the expression
of RANKL (receptor activator of nuclear factor kappa-B ligand) in cartilage, resulting in the activation
of osteoclasts at the osteochondral junction [23]. In addition, deletion of the gene for RXRγ worsens
the growth plate phenotype of VDR knock-out (KO) mice, providing additional evidence for a shared
function of these receptors in cartilage [24].
Similarly, retinoic acid (potentially through retinoic acid receptors, RARs) stimulates
cartilage-to-bone turnover in vitro [25], resembling some of the phenotypes we observed here. However,
since both VDR and RAR are non-permissive partners of RXR, it seems less likely that they mediate
the effects of a specific RXR agonist. Mouse knockout studies also suggest reduced osteoclast activity
in mice with deletions of the genes encoding several other partners of RXR, including PPARγ, LXRs,
and thyroid hormone receptor alpha (reviewed in [26]); thus, activation of the respective heterodimers
by our RXR agonists could contribute to the observed effects. However, it should be noted that in
parallel experiments, administration of the LXR agonist GW3695 did not induce any obvious bone
growth effects. Overall, it seems quite plausible that the complex effects observed in our study could
be due to the combined activation of RXR homodimers and several heterodimeric pairs, potentially
differently in the different cell types involved (chondrocytes, osteoblasts, osteoclasts, and maybe more).
In conclusion, our studies demonstrated that the administration of the selective RXR agonist
SR11237 in skeletally immature rats caused irregular ossification, premature closure of the growth
plate, and reduced bone growth during early postnatal development. Consequently, prolonged RXR
signaling, especially in early life, may result in long-term effects on long bone and joint morphology
and lead to additional pathology (such as osteoarthritis) through joint malalignment, disruption of
normal gait, or direct effects on articular chondrocytes.
4. Materials and Methods
4.1. Animals
Sprague-Dawley rats and pregnant CD1 mice were purchased from Charles River Laboratories
(St. Constant, QC, Canada). Animals were housed in a controlled-temperature (20–25 ◦C),
controlled-humidity (40–60%), ventilated animal room. They were bred in-house and given free
access to water and standard rat or mouse chow. Once born, mouse pups were euthanized by
asphyxiation with CO2 and harvested immediately for organ cultures. The rat pups were housed
with their mother upon birth until harvest at post-natal day 16 (P16). The rats were euthanized by
asphyxiation with CO2. All animal experiments were handled in accordance to the guidelines from
the Canadian Council on Animal Care and were approved by the Animal Use Subcommittee at the
University of Western Ontario (2019-035 (01-06-2019)).
4.2. SR11237 Injections
In each trial, Sprague-Dawley rat pups were divided randomly into two groups. The first group
was given an intraperitoneal injection (IP) of SR11237 (Sigma, Oakville, ON, Canada, #S8951) (pan-RXR
specific agonist) at a concentration of 25 mg per kg body weight (dissolved in DMSO). The second
group was injected with the same volume of DMSO (dimethyl sulfoxide) (Sigma, Oakville, ON, Canada,
#472301) vehicle. Neonates were injected IP once a day from post-natal day 5 to post-natal day 15,
in a similar regime as published for GLP (glucagon-like peptide) agonists in newborns [27], during
a critical window of bone development in the rat [1,5,10–12]. This dose of SR11237 is similar to the
one previously used in vivo [28]. The animals were harvested on post-natal day 16. The animals were
weighed at time of harvest.
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4.3. Tibia Organ Cultures
Tibiae were harvested from newborn CD1 mice and cultured for 4 days in a 37 ◦C humidified
chamber at 5% CO2 as described [29]. They were cultured in serum-free α-MEM (minimum essential
medium eagle) medium (Invitrogen, Burlington, ON, Canada, #12571-063) containing 0.2% bovine
serum albumin (Fisher, Ottawa, ON, Canada, #BP1600-100), 0.25% L-glutamine (Invitrogen, Burlington,
ON, Canada, #25030-081), 0.216 mg/mL β-glycerophosphate (Sigma, Oakville, ON, Canada, #G9891),
0.05 mg/ml ascorbic acid (Sigma, Oakville, ON, Canada, #A4034), and 0.4% penicillin–streptomycin
(Invitrogen, Burlington, ON, Canada, #15140-122) as described [29]. On days 1 and 3, the medium
was replaced, and the bones were treated with DMSO (vehicle) control or SR11237 at 3 increasing
concentrations (0.1, 1, and 5 µM). Total bone length was determined immediately following isolation
and upon experimental completion on day 4, using a Leica S6 D microscope with EC3 camera and Leica
Application Suite version 3.8.0 software (Leica Microsystems Inc., Concord, ON, Canada). Following
fixation in 4% paraformaldehyde overnight at room temperature, the tibiae were prepared for paraffin
embedding and sectioning. The sections were stained with Safranin O/Fast Green as described above.
4.4. Micro-Computed Tomography (MicroCT)
Following harvest of the P16 rats, the left limbs were removed, fixed overnight in 4%
paraformaldehyde (Sigma, Oakville, ON, Canada, #P6148), and stored in 70% ethanol at 4 ◦C until
scanning. Males were scanned using the GE eXplore speCZT at a resolution of 50 micrometers/voxel and
analyzed using the Microview 2.5.0-3943 software (Parallax Innovations, Ilderton, ON, Canada) [30].
4.5. Histology and Immunohistochemistry
Humerus, radius, tibia, and femur were harvested and isolated from the right limbs of all animals.
Long bones were measured, fixed at room temperature for 24 hours with 4% paraformaldehyde
(Sigma, Oakville, ON, Canada, #P6148), and decalcified for 12 days with 5% ethylene diamine
tetra-acetic acid (Sigma, Oakville, ON, Canada, #EDT001.5) in phosphate-buffered saline. Bones from
rats and mouse ex vivo cultures were processed, embedded in paraffin wax, and sectioned by the
Molecular Pathology Laboratory at Robarts Research Institute (London, ON, Canada) at a thickness
of 5 µm. Sections were dewaxed using xylenes and then rehydrated by a series of graded ethanol.
Following rehydration, the sections were chemically stained, or immunohistochemistry was performed.
The sections were stained with 1.5% Safranin O (Sigma, Oakville, ON, Canada, #S8884)/0.01% Fast green
(Harleco (Millipore), Etibocoke, ON, Canada, #210-12) as described [31–33], picro-sirius red (Picric acid
saturated solution Sigma, Oakville, ON, Canada, #P6744-1GA and Sirius Red F3B Sigma, Oakville,
ON, Canada, #36-554-8) as described [30], tartrate-resistant acid phosphatase (TRAP) (Sigma, Oakville,
ON, Canada, #387-A) according to the manufacturer’s instructions with minor changes (60 minute
Triton-X incubation), and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)
(Calbiochem (Millipore), Etobicoke, ON, Canada, #QIA33) as instructed by the manufacturer’s manual.
Immunohistochemistry was performed as described [31] with primary antibodies against PCNA
(proliferating cell nuclear antigen) (Cell Signaling, Danvers, MA, USA, #2586) at a concentration of
1:5000, P57 (Santa Cruz, Dallas, Texas, USA, #sc-8298) at a concentration of 1:200, or SOX9 (R&D,
Minneapolis, MN, USA, #AF3075) at a concentration of 1:300. Antigen retrieval was completed
using 0.1% Triton-X in water, and slides without primary antibody were used as negative controls.
All antibody incubations were performed overnight at 4 ◦C. After washing, secondary antibodies
conjugated to horseradish peroxidase (either Santa Cruz, Dallas, TX, USA, #sc-2004 or sc-2020) were
used for 1 hour at room temperature, followed by colorimetric detection by diaminobenzidine substrate
(Dako, Santa Clara, CA, USA, #K3468). Following this, the sections were counterstained using methyl
green (Sigma, Oakville, ON, Canada, #198080). A total of 6 sections per sample were used, with at
least 3 independent samples (animals) for each assay. Images were captured directly with a Leica
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DM1000 microscope and Leica DFC295 camera or stitched together from multiple individual images
using Leica Application Suite software.
4.6. Statistical Analyses
GraphPad Prism software version 6 (GraphPad Software Inc., San Diego, CA, USA) was used to
conduct all statistical analysis. Animals weights and bone lengths were analyzed using a non-parametric
Mann–Whitney unpaired two-tailed t-test with five independent trials. Organ culture tibial lengths
were analyzed using a Kruskal–Wallis one-way ANOVA with five independent trials with Dunn’s
post-hoc test. Significance was assumed for p values less than 0.05 for all statistical tests.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/20/
5198/s1.
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EO Endochondral ossification
RXR Retinoid X receptor
SOX9 Sex-determining region-box 9
RUNX2 Runt-related transcription factor 2
MEF2C Myocyte enhancer factor-2c
PPAR Peroxisome proliferator-activated receptor
FXR Farnesoid X receptor
LXR Liver X receptor
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